SEARCH

SEARCH BY CITATION

Literature Cited

  • 1
    Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:27152729.
  • 2
    Hermann-Kleiter N, Baier G. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood 2010;115:29892997.
  • 3
    Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation—How much of the promise has been realized? Nat Med 2005;11:605613.
  • 4
    Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623653.
  • 5
    Mancini M, Toker A. NFAT proteins: Emerging roles in cancer progression. Nat Rev Cancer 2009;9:810820.
  • 6
    Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374384.
  • 7
    Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997;100:18941901.
  • 8
    Fukudo M, Yano I, Masuda S, Fukatsu S, Katsura T, Ogura Y, Oike F, Takada Y, Tanaka K, Inui K. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clin Pharmacol Ther 2005;78:168181.
  • 9
    Fukudo M, Yano I, Masuda S, Okuda M, Inui K. Distinct inhibitory effects of tacrolimus and cyclosporin a on calcineurin phosphatase activity. J Pharmacol Exp Ther 2005;312:816825.
  • 10
    Sanquer S, Schwarzinger M, Maury S, Yakouben K, Rafi H, Pautas C, Kuentz M, Barouki R, Cordonnier C. Calcineurin activity as a functional index of immunosuppression after allogeneic stem-cell transplantation. Transplantation 2004;77:854858.
  • 11
    Sommerer C, Meuer S, Zeier M, Giese T. Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta 2012;413(17–18):13791386.
  • 12
    Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010;89:14171423.
  • 13
    Zahn A, Schott N, Hinz U, Stremmel W, Schmidt J, Ganten T, Gotthardt D, Meuer S, Zeier M, Giese T, et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: The first clinical trial in liver allograft recipients. Liver Transpl 2011;17:466473.
  • 14
    Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: A new concept of individual immunosuppression. Transplantation 2008;85:1521.
  • 15
    Sommerer C, Konstandin M, Dengler T, Schmidt J, Meuer S, Zeier M, Giese T. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006;82:12801285.
  • 16
    Sommerer C, Zeier M, Czock D, Schnitzler P, Meuer S, Giese T. Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011;33:373379.
  • 17
    Giese T, Sommerer C, Zeier M, Meuer S. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009;132:305311.
  • 18
    Giese T, Sommerer C, Zeier M, Meuer S. Approaches towards individualized immune intervention. Dig Dis 2010;28:4550.
  • 19
    George TC, Fanning SL, Fitzgerald-Bocarsly P, Medeiros RB, Highfill S, Shimizu Y, Hall BE, Frost K, Basiji D, Ortyn WE, et al. Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. J Immunol Methods 2006;311:117129.
  • 20
    Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O'Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ Jr., et al. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in tumor-associated T cells. Cancer Immun 2013;13:14.
  • 21
    Deptala A, Bedner E, Gorczyca W, Darzynkiewicz Z. Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC). Cytometry 1998;33:376382.
  • 22
    Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:22052232.
  • 23
    Maguire O, Collins C, O'Loughlin K, Miecznikowski J, Minderman H. Quantifying nuclear p65 as a parameter for NF-kappaB activation: Correlation between ImageStream cytometry, microscopy, and Western blot. Cytometry A 2011;79A:461469.
  • 24
    Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803807.
  • 25
    Garcia-Rodriguez C, Rao A. Requirement for integration of phorbol 12-myristate 13-acetate and calcium pathways is preserved in the transactivation domain of NFAT1. Eur J Immunol 2000;30:24322436.
  • 26
    Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit 2004;26:506515.
  • 27
    Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:1333.
  • 28
    Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 1995;17:596601.
  • 29
    Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation 2000;70:327335.
  • 30
    Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004;5:273282.
  • 31
    Organ procurement and transplantation network and scientific registry of transplant recipients 2010 data report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 2012;12 (Suppl 1):1156..
  • 32
    Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995;17:681684.
  • 33
    Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 2007;293:F616F623.
  • 34
    Andreucci M, Faga T, Lucisano G, Uccello F, Pisani A, Memoli B, Sabbatini M, Fuiano G, Michael A. Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells. Chem Biol Interact 2010;185:253262.
  • 35
    Kamienska E, Ociepa T, Wysocki M, Kurylak A, Matysiak M, Urasinski T, Urasinska E, Domagala W. Activation of NF-kB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: Relation to other prognostic factors. Pol J Pathol 2011;62:511.
  • 36
    Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol 2013;304:F1375F1389.
  • 37
    Lopez-Rodriguez C, Antos CL, Shelton JM, Richardson JA, Lin F, Novobrantseva TI, Bronson RT, Igarashi P, Rao A, Olson EN. Loss of NFAT5 results in renal atrophy and lack of tonicity-responsive gene expression. Proc Natl Acad Sci USA 2004;101:23922397.
  • 38
    Hernandez-Ochoa EO, Robison P, Contreras M, Shen T, Zhao Z, Schneider MF. Elevated extracellular glucose and uncontrolled type 1 diabetes enhance NFAT5 signaling and disrupt the transverse tubular network in mouse skeletal muscle. Exp Biol Med (Maywood) 2012;237:10681083.
  • 39
    Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity 2001;14:1320.
  • 40
    Graef IA, Chen F, Chen L, Kuo A, Crabtree GR. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001;105:863875.